NCT07017868Recruiting
Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients
Source: ClinicalTrials.gov · Last updated 12 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokines
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 4 Jun 2025
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Sohag University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07017868
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Jan 2025 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- ● Individuals with other autoimmune diseases.
- Patients receive any hyperuricemia treatment
- Pregnancy
- Malignancy
- Diabetes.
- Hypertension.
- Heart failure.
- Hepatic diseases.
- Chronic renal failure other than lupus nephritis.
- Renal artery stenosis.
- Renal vein thrombosis.
- Intrarenal arteriovenous fistula.
- Obstructive nephropathy.
- Urinary tract obstruction that could affect RI of intra renal arteries.
- Uncooperative patients.
- Patients not able and willing to give written informed consent.
Who the study is looking for
- ● Aged ≥18 years.
- SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls.
- Patients cooperative and can answer questions.
- Patients who are able and willing to give written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Hospital Coordinator of this site? Confirm its status | Sohag | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.